RU2006132719A - Способ повышения биологической доступности оспемифена - Google Patents
Способ повышения биологической доступности оспемифена Download PDFInfo
- Publication number
- RU2006132719A RU2006132719A RU2006132719/15A RU2006132719A RU2006132719A RU 2006132719 A RU2006132719 A RU 2006132719A RU 2006132719/15 A RU2006132719/15 A RU 2006132719/15A RU 2006132719 A RU2006132719 A RU 2006132719A RU 2006132719 A RU2006132719 A RU 2006132719A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- meal
- administered
- symptoms
- time
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 claims 15
- 235000012054 meals Nutrition 0.000 claims 12
- 208000024891 symptom Diseases 0.000 claims 8
- 206010003694 Atrophy Diseases 0.000 claims 4
- 230000037444 atrophy Effects 0.000 claims 4
- 235000013305 food Nutrition 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims 2
- 229960003969 ospemifene Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (18)
1. Способ повышения биологической доступности терапевтически активного соединения формулы (I)
или его геометрического изомера, стереоизомера, фармацевтически приемлемой соли, сложного эфира или метаболита, отличающийся тем, что указанное соединение вводится орально индивидууму в связи с приемом пищи.
2. Способ по п.1, где соединение (I) представляет собой оспемифен.
3. Способ по п.1, где соединение вводят в момент времени, находящийся в промежутке, ограниченном 1 ч до начала приема пищи и 2 ч после начала приема пищи.
4. Способ по п.3, где соединение вводят в момент времени, находящийся в промежутке, ограниченном началом в момент времени во время приема пищи и до истечения 1 ч после начала приема пищи.
5. Способ по п.4, где соединение вводят в момент времени не позднее, чем 0,5 ч после начала приема пищи.
6. Способ по п.1, где пища представляет собой любой пищевой продукт, имеющий питательную ценность и способный вызвать секрецию желчных кислот.
7. Способ по п.1, где соединение применяют для лечения или профилактики остеопороза.
8. Способ по п.1, где соединение применяют для лечения или профилактики симптомов, связанных с атрофией кожи или атрофией эпителия или слизистых оболочек.
9. Способ по п.8, где симптомы представляют собой мочевые симптомы или влагалищные симптомы.
11. Применение по п.10, где соединение (I) представляет собой оспемифен.
12. Применение по п.10, где соединение вводят в момент времени, находящийся в промежутке, ограниченном 1 ч до начала приема пищи и 2 ч после начала приема пищи.
13. Применение по п.12, где соединение вводят в момент времени, находящийся в промежутке, ограниченном началом в момент времени во время приема пищи и до истечения 1 ч после начала приема пищи.
14. Применение по п.13, где соединение вводят в момент времени не позднее, чем 0,5 ч после начала приема пищи.
15. Применение по п.10, где пища представляет собой любой пищевой продукт, имеющий питательную ценность и способный вызвать секрецию желчных кислот.
16. Применение по п.10, где соединение применяют для лечения или профилактики остеопороза.
17. Применение по п.10, где соединение применяют для лечения или профилактики симптомов, связанных с атрофией кожи или атрофией эпителия или слизистых оболочек.
18. Применение по п.17, где симптомы представляют собой мочевые симптомы или влагалищные симптомы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/777,211 | 2004-02-13 | ||
US10/777,211 US8236861B2 (en) | 2004-02-13 | 2004-02-13 | Method for enhancing the bioavailablity of ospemifene |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006132719A true RU2006132719A (ru) | 2008-03-20 |
RU2385716C2 RU2385716C2 (ru) | 2010-04-10 |
Family
ID=34837941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006132719/15A RU2385716C2 (ru) | 2004-02-13 | 2005-01-14 | Способ повышения биологической доступности оспемифена |
Country Status (21)
Country | Link |
---|---|
US (5) | US8236861B2 (ru) |
EP (1) | EP1713458B1 (ru) |
JP (2) | JP5577011B2 (ru) |
CN (1) | CN1925847A (ru) |
AT (1) | ATE387910T1 (ru) |
AU (1) | AU2005211958B2 (ru) |
BR (1) | BRPI0507661A (ru) |
CA (1) | CA2556089C (ru) |
CY (2) | CY1111014T1 (ru) |
DE (1) | DE602005005165T2 (ru) |
DK (1) | DK1713458T5 (ru) |
ES (1) | ES2302177T3 (ru) |
HU (1) | HUS1500030I1 (ru) |
LT (1) | LTC1713458I2 (ru) |
LU (1) | LU92736I2 (ru) |
MX (1) | MXPA06009274A (ru) |
NO (2) | NO337656B1 (ru) |
PL (1) | PL1713458T3 (ru) |
PT (1) | PT1713458E (ru) |
RU (1) | RU2385716C2 (ru) |
WO (1) | WO2005077350A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
EP1742618B1 (en) | 2004-05-04 | 2012-08-22 | Hormos Medical Ltd. | Liquid oral formulations of ospemifene |
AU2006339325A1 (en) * | 2005-11-09 | 2007-09-07 | Hormos Medical Ltd. | Formulations of fispemifene |
US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
EA201500845A1 (ru) * | 2005-11-28 | 2016-04-29 | Джи Ти Икс, ИНК. | Агенты, связывающиеся с ядерными рецепторами |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
CN101636372B (zh) * | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
CN103739456A (zh) * | 2013-12-03 | 2014-04-23 | 镇江圣安医药有限公司 | 2-(对-((z-4-氯-1,2-二苯基-1-丁烯基)苯氧基)乙醇的新型衍生物及其应用 |
GR1009542B (el) | 2018-04-25 | 2019-06-07 | Φαρματεν Α.Β.Ε.Ε. | Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων |
WO2019217924A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
ES2255294T3 (es) * | 1998-08-07 | 2006-06-16 | Chiron Corporation | Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos. |
US6219674B1 (en) | 1999-11-24 | 2001-04-17 | Classen Immunotherapies, Inc. | System for creating and managing proprietary product data |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6653639B1 (en) * | 2000-10-17 | 2003-11-25 | Nikon Corporation | Chuck for mounting reticle to a reticle stage |
CA2438816A1 (en) | 2001-02-22 | 2002-09-06 | Classen Immunotherapies, Inc. | Improved algorithms and methods for products safety |
FR2826811B1 (fr) | 2001-06-27 | 2003-11-07 | France Telecom | Procede d'authentification cryptographique |
CA2484542C (en) | 2002-06-06 | 2010-11-02 | Hormos Medical Corporation | Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US20050187302A1 (en) | 2004-02-23 | 2005-08-25 | Hormos Medical Corporation | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
US8758821B2 (en) | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
US20060293294A1 (en) | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
-
2004
- 2004-02-13 US US10/777,211 patent/US8236861B2/en active Active
-
2005
- 2005-01-14 PL PL05701734T patent/PL1713458T3/pl unknown
- 2005-01-14 JP JP2006552639A patent/JP5577011B2/ja active Active
- 2005-01-14 AT AT05701734T patent/ATE387910T1/de active
- 2005-01-14 BR BRPI0507661-7A patent/BRPI0507661A/pt not_active Application Discontinuation
- 2005-01-14 EP EP05701734A patent/EP1713458B1/en active Active
- 2005-01-14 DE DE602005005165T patent/DE602005005165T2/de active Active
- 2005-01-14 PT PT05701734T patent/PT1713458E/pt unknown
- 2005-01-14 WO PCT/FI2005/000018 patent/WO2005077350A1/en active IP Right Grant
- 2005-01-14 RU RU2006132719/15A patent/RU2385716C2/ru active
- 2005-01-14 DK DK05701734T patent/DK1713458T5/da active
- 2005-01-14 MX MXPA06009274A patent/MXPA06009274A/es active IP Right Grant
- 2005-01-14 CN CNA200580004550XA patent/CN1925847A/zh active Pending
- 2005-01-14 ES ES05701734T patent/ES2302177T3/es active Active
- 2005-01-14 CA CA2556089A patent/CA2556089C/en active Active
- 2005-01-14 AU AU2005211958A patent/AU2005211958B2/en not_active Ceased
-
2006
- 2006-09-05 NO NO20063960A patent/NO337656B1/no unknown
-
2008
- 2008-04-24 CY CY20081100456T patent/CY1111014T1/el unknown
-
2012
- 2012-07-06 US US13/543,166 patent/US8470890B2/en not_active Expired - Lifetime
-
2013
- 2013-05-29 US US13/904,818 patent/US8772353B2/en not_active Expired - Lifetime
-
2014
- 2014-05-12 JP JP2014098549A patent/JP6023119B2/ja active Active
- 2014-06-20 US US14/310,822 patent/US9241915B2/en not_active Expired - Fee Related
-
2015
- 2015-06-10 LU LU92736C patent/LU92736I2/xx unknown
- 2015-06-16 HU HUS1500030C patent/HUS1500030I1/hu unknown
- 2015-06-25 LT LTPA2015023C patent/LTC1713458I2/lt unknown
- 2015-07-08 CY CY2015027C patent/CY2015027I1/el unknown
- 2015-11-25 NO NO20151603A patent/NO339190B1/no unknown
- 2015-12-16 US US14/971,252 patent/US9855224B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006132719A (ru) | Способ повышения биологической доступности оспемифена | |
JP6941109B2 (ja) | Fxrアゴニストを使用するための方法 | |
AU2020203101B2 (en) | Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability | |
JP6379143B2 (ja) | エクセナチドの経口投与用の方法及び組成物 | |
JP7053478B2 (ja) | Fxrアゴニストを使用するための方法 | |
US10857118B2 (en) | Compositions and methods for treating intestinal hyperpermeability | |
CA2515293A1 (en) | Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage | |
CA3013186A1 (en) | Methods for using fxr agonists | |
RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
JP2008540394A5 (ru) | ||
RU2006141647A (ru) | Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний | |
RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
NO20030273L (no) | Fremgangsmåte for behandling av klimakterieforstyrrelser hos kvinner i löpet av eller etter menopause | |
JP2008247874A (ja) | 育毛促進剤 | |
RU2004124840A (ru) | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений | |
RU2353358C2 (ru) | Производные прегабалина для лечения приливов | |
US20210290576A1 (en) | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease | |
CA2598786A1 (en) | Composition and method for increasing the anabolic state of muscle cells | |
JP2023501058A (ja) | ベータ-ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物 | |
JP2023554524A (ja) | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 | |
US20050137256A1 (en) | Use of arachidonic acid as a method of increasing skeletal muscle mass | |
TH54911B (th) | สูตรปลดปล่อยที่ควบคุม | |
RU2005113169A (ru) | Фармацевтическая форма введения через слизистую оболочку |